2026 Kff

• The FDA approved a third over-the-counter version of naloxone nasal spray on Tuesday, June 16, to increase accessibility and reduce costs for overdose reversal. • Separately, a reported disruption in breast biopsy services is expected to impact patient care and may necessitate adjustments to clinical management. • These developments highlight critical shifts in public health accessibility and the operational challenges facing diagnostic medical services.

• In the phase III INDIGO trial, the investigational monoclonal antibody obexelimab substantially outperformed a placebo in treating immunoglobulin (Ig)G4-related disease. • This development positions obexelimab to compete with the only drug currently approved for the condition, potentially offering patients a new therapeutic option. • Separately, the CDC and state partners published a report in Morbidity and Mortality Weekly Report urging clinicians to increase screening for brucellosis.

• Uganda ordered the closure of its border with Congo on Wednesday, May 27, 2026, following a surge of suspected Ebola cases in the neighboring country. • The decision follows the confirmation of Ebola cases within Uganda after local health workers were exposed to infected Congolese patients. • This outbreak involves the Bundibugyo virus, a rare strain of Ebola that currently lacks approved vaccines or medicines, increasing the risk of contagion in East Africa.